Syk, a novel therapeutic target for PTLD, drives Epstein Barr Virus B cell lymphoma growth and survival through the PI3K/Akt pathway Hatton, O. L., Lambert, S., Vaysberg, M., Krams, S. M., Esquivel, C. O., Martinez, O. M. AMER ASSOC IMMUNOLOGISTS. 2009

View details for Web of Science ID 000209763603142